KC-3713

CHOK1-IGSF11 Cell Line

×
Please enable JavaScript in your browser to complete this form.
34646
Home » 细胞系 » CHOK1-IGSF11 Cell Line

Background of CHOK1-IGSF11 Cell Line

IGSF11 (Immunoglobulin Superfamily Member 11) is a Protein Coding gene. The immunoglobulin superfamily member 11 (IgSF11), a homophilic adhesion molecule that preferentially expressed in the brain, is a dual-binding partner of the postsynaptic scaffolding protein PSD-95 and AMPA glutamate receptors (AMPARs). IgSF11 required PSD-95 binding for its excitatory synaptic localization. It functions as a cell adhesion molecule through homophilic to interaction timulates cell growth. Diseases associated with IGSF11 include Gastric Cancer.

Specifications

Catalog NumberKC-3713
Cell Line NameCHOK1-IGSF11 Cell Line
Host Cell LineCHOK1
DescriptionStable CHOK1 cell line expressing exogenous human IGSF11 gene
QuantityTwo vials of frozen cells (≥2-106/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640 + 20% FBS + 10% DMSO
Propagation MediumRPMI1640 + 10% FBS + 10μg/ml Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/ml
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 24 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

CHOK1-IGSF11 Cell Line was generated using a lentiviral vector expressing the human IGSF11 equence.

Characterization

Figure 1: Characterization of human IGSF11 overexpression in the CHO-K1 IGSF11 stable clone using FACS.

Figure 2: Characterization of human IGSF11 and its mutants overexpressing in CHOK1 stable clones using PCR sequencing.

Cell Resuscitation

1. Prewarm culture medium (RPMI1640 supplemented with 10% FBS and 10μg/ml Puromycin)in a 37°C water bath. 2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes. 3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol. 4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium. 5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet. 6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask. 7. Incubate the flask at 37°C, 5% CO2 incubator. 8. Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% RPMI1640 + 20% FBS + 10% DMSO) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium. 6. Aliquot 1 mL of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage

References

1. Jang S, Oh D, Lee Y, Hosy E, Shin H, van Riesen C, Whitcomb D, Warburton JM, Jo J, Kim D, Kim SG, Um SM, Kwon SK, Kim MH, Roh JD, Woo J, Jun H, Lee D, Mah W, Kim H, Kaang BK, Cho K, Rhee JS, Choquet D, Kim E. Synaptic adhesion molecule IgSF11 regulates synaptic transmission and plasticity. Nat Neurosci. 2016 Jan;19(1):84-93. doi: 10.1038/nn.4176. Epub 2015 Nov 23. PMID: 26595655; PMCID: PMC5010778. 2. Ghouzlani A, Rafii S, Karkouri M, Lakhdar A, Badou A. The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis. Front Oncol. 2021 Feb 2;10:608609. doi: 10.3389/fonc.2020.608609. PMID: 33604291; PMCID: PMC7884863. 3. ang, XY., Xiong, YL., Shi, XG. et al. IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy. Biomark Res 10, 49 (2022).
Please enable JavaScript in your browser to complete this form.